SAN DIEGO, Feb. 2, 2017 — Medical Marijuana, Inc. (OTC PINK:MJNA), the first publicly traded cannabis company in the United States, announced today that its subsidiary HempMeds Brasil™ has launched a new website featuring brand information, a navigable web interface layout, and online services available for medical marijuana customers.
HempMeds Brasil™ is the first company to offer legal medical cannabis products to Brazil after receiving approval to import to those suffering from specific medical conditions. The new site comes on the heels of three major developments with the company. HempMeds Brasil™ has recently announced an expanded management team, approved importation of RSHO-X™, and establishment of a new working relationship with Paragon Meds.
“We are excited to announce the launch of a new website that we are confident will bring better service and availability of our products to consumers in Brazil,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. “We have reworked the website to benefit not only our customers, but those wishing to receive educational info about our range of products. Everyone will be able to easily access detailed information on our brands, the history of our company, the background behind the items we offer, and content aimed at providing insight into the very success stories that make our products so great.”
The new site will feature a form that would enable potential customers to speak directly to HempMeds Brasil™ team members, allowing them to receive references to doctors for access to CBD hemp oil products. Featured in the site are displays detailing pertinent information aimed at extending convenience for current customers. Established patients will also gain access to prescription delivery services, industry updates, treatment options and product details. Customers can also use HempMeds Brasil™ live support for any additional questions or needs – Call: 21 4042 2095.
About HempMeds Brasil™
HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system. As of 2015 ANVISA has allowed cannabidiol treatments for any medical condition a doctor sees could help the patient. HempMeds Brasil™ has had doctor prescriptions for Epilepsy, Parkinson’s, Alzheimer’s, Cancer, Autism, Multiple Sclerosis and Chronic Pain to date and is working on additional approvals for multiple indications.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer